See other companies on Welcome to the Jungle
Ataraxis AI
AI precision medicine for cancer diagnostics
- 1-20 employees
- Healthcare
- B2B
- Artificial Intelligence
- Biology
- SaaS
- Midtown South, New York, NY
Jump to section
Company mission
To empower physicians with advanced tools that pinpoint the most effective treatments, enhancing patient care and driving better health outcomes.
Our take
When treating patients with cancer, a critical issue is varied progression rates. Some cancers are aggressive while others are slow growing, making it difficult to decide the best treatment plan and avoid unnecessary treatments. Ataraxis AI is tackling this problem, beginning with breast cancer.
The company has developed an AI-powered diagnostic tool called Ataraxis Breast, which assesses whether a breast cancer is high or low risk. A recent study suggests that the company's system is up to 30% more accurate than the current standard. This allows doctors to make more informed decisions, taking the predicted progression into account.
Founded in 2023, the company is already making impressive strides, emerging from stealth with promising seed funds. Ataraxis AI plans to enhance its tools further and expand its product line into other cancers, with its software made available to healthcare providers by 2025.
Steph
Company Specialist at Welcome to the Jungle
Funding (1 round)
Oct 2024
$4m
SEED
Total funding: $4m
Leadership
Jan Witowski
(Co-Founder & CEO)A Physician-Scientist with over 10 years of medical image processing experience. They previously worked at Harvard Medical School, Massachusetts General Hospital, and NYU Langone Health, where they led research projects focused on AI and medical imaging.
Krzysztof Geras
(Co-Founder & Chief Scientist)Assistant Professor at NYU Grossman School of Medicine in the Department of Radiology. Also affiliated at NYU Center for Data Science and Courant Institute of Mathematical Sciences.